$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
028-123456789
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
medicaldrugs
medicaldrugs
Detailed explanation of the reference cost and different purchasing channels of Caposetinib Tablets (Caposetinib)
2026-02-01 22:25:32
Check Details
Guselkumab market reference price and detailed description of drug purchasing channels in different regions
2026-02-01 22:25:32
Check Details
Tenapano (Ventile) tablets efficacy, functions and indications
2026-02-01 22:25:32
Check Details
Revumenib-REVUFORJ 2025 Market Reference Price and Purchasing Channel Description Analysis
2026-02-01 22:25:32
Check Details
Can I still take Guanfacine after taking it for three years? and long-term medication safety and efficacy observation and analytical explanation
2026-02-01 22:25:32
Check Details
Pacritinib clinical efficacy observation, patient feedback and indication summary and analysis
2026-02-01 22:25:32
Check Details
Analysis of common side effects and clinical safety of Letermovir (Premin)
2026-02-01 22:25:32
Check Details
Etrasimod - Latest news on Velsipity and domestic and overseas launch trends
2026-02-01 22:25:32
Check Details
Analysis of Lusutrombopag 2025 Medical Insurance Price and Reimbursement Policy
2026-02-01 22:25:32
Check Details
Introduction to fezolinetant
2026-02-01 22:25:32
Check Details
What exactly is obeticholic acid and what are its ingredients?
2026-02-01 22:25:32
Check Details
Final pricing of neratinib/neratinib in 2026
2026-02-01 22:25:32
Check Details
1
2
...
2340
2341
2342
2343
2344
2345
2346
...
2438
2439
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
User Agreement
2
Herceptin Hylecta treats HER2-positive breast cancer and only needs to be injected subcutaneously and only used once every three weeks
3
What is the most important information I should know about WELIREG?
4
How to take and store WELIREG
5
How to take TRUSELTIQ correctly
6
How to deal with LONSURF side effects (1)
7
How to deal with LONSURF side effects (2)
8
Cabozantinib (Cabometyx)-new indication approved
9
What should I pay attention to when using atezolizumab/Tecentriq?
10
Darzalex Faspro, Kyprolis and dexamethasone "three swords combined" to treat multiple myeloma
11
Rituximab combined with chemotherapy approved in the United States for pediatric patients with specific malignant tumors
12
Lenvatinib and pembrolizumab trial results in unresectable hepatocellular carcinoma